Hematology Activities
Novel Reversal Agents to Safely and Effectively Treat Direct Oral Anticoagulant Bleeding: Education for the Health-System Pharmacist
0290-0000-21-245-H01-P
Apply the most recent evidence-based guidelines to the selection of direct oral anticoagulant (DOAC) reversal agents in reversal of major bleeding associated with the use of DOACs.
1.00
Managed Care Strategies to Support Access to CAR T-Cell Therapy
0290-0000-21-243-H01-P
Examine recent studies for approved and emerging chimeric antigen receptor-modified T cell (CAR) T-cell therapies and the impact of these treatments on the future paradigm of cancer care
1.00
A Focus on BTK Inhibitors in B-Cell Malignancies (Part 1 of 2): Foundations of Evidence for Use and Management Strategies for Cardiac and Bleeding Adverse Effects
0290-0000-21-234-H01-P
Outline the efficacy of oral BTK inhibitors across B-cell malignancies including a focus on emerging clinical data
0.75
A Focus on BTK Inhibitors in B-Cell Malignancies (Part 2 of 2): Implementing Digital Technology Tools Within Health-Systems to Improve Adherence and Patient Support
0290-0000-21-235-H01-P
This podcast will emphasize the role pharmacists play in improving adherence and patient management through the use of digital and telemedicine technologies in this patient population.
0.75